Ipsogen Launches New Cancer Diagnostic Test
Posted on: Monday, 2 June 2008, 12:22 CDT
Ipsogen has announced that it is entering the breast cancer diagnostic market with the European launch of MapQuant Dx Genomic Grade.
MapQuant Dx Genomic Grade is a molecular diagnostic test to accurately measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.
According to the company, MapQuant Dx Genomic Grade test directly measures the expression of the 97 genes that best characterize high-grade versus low-grade tumors. It can resolve these 'grade 2' tumors into either 'grade 1' or 'grade 3' tumors in 80 % of cases.
MapQuant Dx Genomic Grade test is said to be especially useful when tumor grade information can be decisive for prescribing chemotherapy. According to most guidelines, this is the case for hormone-sensitive (ER+) node-negative (N-) invasive breast carcinoma.
Source: Datamonitor
Related Articles
- New Genomic Test for Coronary Artery Disease Now Available at The Heart & Vascular Center of Arizona
- CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
- Genomic Test Personalizes Breast Cancer Treatment
- Alhambra Unified School District Raises 7th-Grade California Standards Test Scores With Vantage Learning's MY Access! Online Writing Tool
- This Week on Your Cancer Today: New Genomic Test Announced By Duke University
- Promethean Offers Bilingual / ESOL Interactive Curriculum to Help Schools With ELL Students Meet Fifth Grade NCLB Science Testing Requirements
- The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Genomic Health, Inc. Announce Positive Early Results in Development of Genomic Test for Colon Cancer Prognosis
- Devon Medical Supplies, SafeTip(TM) Syringe Make the Grade in Clinical Testing
- Oncotech Offers New Genomic Test for Lung Cancer
- New Approach to Genomic Testing Identifies Women With Low Risk of Breast Cancer Recurrence
 |
 |
User Comments (0)
RSS Feeds